Colonic butyrate administration modulates fear memory but not the acute stress response in men: A randomized, triple-blind, placebo-controlled trial

被引:6
|
作者
Dalile, Boushra [1 ,2 ,3 ,5 ]
Fuchs, Annalena [1 ,2 ]
La Torre, Danique [1 ,2 ]
Vervliet, Bram [2 ,3 ]
Van Oudenhove, Lukas [1 ,2 ,4 ]
Verbeke, Kristin [1 ]
机构
[1] Katholieke Univ Leuven, Translat Res Ctr Gastrointestinal Disorders TARGID, Dept Chron Dis & Metab, Leuven, Belgium
[2] Univ Leuven, Leuven Brain Inst, Leuven, Belgium
[3] Katholieke Univ Leuven, Fac Psychol & Educ Sci, Lab Biol Psychol Brain & Cognit, Leuven, Belgium
[4] Dartmouth Coll, Dept Psychol & Brain Sci, Cognit & Affect Neurosci Lab, Hanover, NH USA
[5] Univ Louvain, Dept Pathophysiol, Translat Res Ctr Gastrointestinal Disorders, O &N 1 Herestr 49 Box 701, Louvain, Belgium
来源
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 2024年 / 131卷
关键词
Stress; Cortisol; Butyrate; Gut-brain axis; Fear conditioning; CHAIN FATTY-ACIDS; LONG-TERM-MEMORY; HISTONE ACETYLATION; PSYCHOSOCIAL STRESS; SEX-DIFFERENCES; HUMAN BRAIN; HDAC; MICROBIOTA; EXPRESSION; INHIBITORS;
D O I
10.1016/j.pnpbp.2024.110939
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Short-chain fatty acids (SCFAs) are produced in the colon following bacterial fermentation of dietary fiber and are important microbiota-gut-brain messengers. However, their mechanistic role in modulating psychobiological processes that underlie the development of stress- and anxiety-related disorders is scarcely studied in humans. We have previously shown that colonic administration of a SCFA mixture (acetate, propionate, butyrate) lowers the cortisol response to stress in healthy participants, but does not impact fear conditioning and extinction. To disentangle the effects of the three main SCFAs, we examined whether butyrate alone would similarly modulate these psychobiological responses in a randomized, triple -blind, placebo-controlled intervention study in 71 healthy male participants (Mage = 25.2, MBMI = 22.7 [n = 35 butyrate group, n = 36 placebo group]). Colondelivery capsules with pH -dependent coating were used to administer 5.28 g of butyrate or placebo daily for one week. Butyrate administration significantly increased serum butyrate concentrations without modulating serum acetate or propionate, nor fecal SCFAs. Butyrate administration also significantly modulated fear memory at the subjective but not physiological levels. Contrary to expectations, no changes in subjective nor neuroendocrine responses to acute stress were evident between the treatment groups from pre- to post -intervention. We conclude that colonic butyrate administration alone is not sufficient to modulate psychobiological stress responses, unlike administration of a SCFA mixture. The influence of colonic and systemic butyrate on fear memory and the persistence of fear extinction should be further systematically investigated in future studies.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Gut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for depressive symptoms
    Chahwan, Bahia
    Kwan, Sophia
    Isik, Ashling
    van Hemert, Saskia
    Burke, Catherine
    Roberts, Lynette
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 253 : 317 - 326
  • [32] Acute Effect of Topical Menthol on Chronic Pain in Slaughterhouse Workers with Carpal Tunnel Syndrome: Triple-Blind, Randomized Placebo-Controlled Trial
    Sundstrup, Emil
    Jakobsen, Markus D.
    Brandt, Mikkel
    Jay, Kenneth
    Colado, Juan Carlos
    Wang, Yuling
    Andersen, Lars L.
    REHABILITATION RESEARCH AND PRACTICE, 2014, 2014
  • [33] Effect of royal jelly on premenstrual syndrome: a randomized, triple-blind, placebo controlled trial
    Taavoni, Simin
    Barkhordari, Fatemeh
    Gooshegir, Seid Ashrafedin
    Haghani, Hamid
    GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 : 52 - 52
  • [34] Re: Randomized, Triple-Blind, Placebo-Controlled Clinical Trial Examining the Effects of Alpha-Lipoic Acid Supplement on the Spermatogram and Seminal Oxidative Stress in Infertile Men
    Niederberger, Craig
    JOURNAL OF UROLOGY, 2016, 195 (04): : 1076 - 1076
  • [35] Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial
    Jaafarinia, Asma
    Kafami, Behzad
    Sahebnasagh, Adeleh
    Saghafi, Fatemeh
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2022, 22 (01)
  • [36] Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial
    Inês Bernardino
    Ana Dionísio
    Miguel Castelo-Branco
    Scientific Reports, 12
  • [37] Antihypertensive and antihyperlipemic of spirulina (Arthrospira platensis) sauce on patients with hypertension: A randomized triple-blind placebo-controlled clinical trial
    Far, Zohreh Ghaem
    Babajafari, Siavash
    Kojuri, Javad
    Mohammadi, Salman
    Nouri, Mehran
    Rostamizadeh, Pouya
    Rahmani, Mohammad Hossein
    Azadian, Mohsen
    Ashrafi-Dehkordi, Elham
    Zareifard, Alireza
    Vafa, Reza Golchin
    Mazloomi, Seyed Mohammad
    PHYTOTHERAPY RESEARCH, 2021, 35 (11) : 6181 - 6190
  • [38] Is cinnarizine/betahistine combination superior to respective monotherapies in treatment of vertigo? Comment on a randomized triple-blind placebo-controlled trial
    Kiumarth Amini
    Maryam Taghizadeh-Ghehi
    European Journal of Clinical Pharmacology, 2020, 76 : 607 - 608
  • [39] The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer’s disease: a randomized, triple-blind, placebo-controlled trial
    Luciana L. Louzada
    Flávio V. Machado
    Juliana L. Quintas
    Guilherme A. Ribeiro
    Mônica V. Silva
    Dayde L. Mendonça-Silva
    Bruno S. B. Gonçalves
    Otávio T. Nóbrega
    Einstein F. Camargos
    Neuropsychopharmacology, 2022, 47 : 570 - 579
  • [40] Comment on "Is cinnarizine/betahistine combination superior to respective monotherapies in treatment of vertigo? A randomized triple-blind placebo-controlled trial"
    Majdi, Alireza
    Alavi, Seyed Ahmad
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (04) : 609 - 610